AbbVie vs argenx stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
argenx is more profitable, grows faster, is cheaper for its profits and has less debt.
Side by side
| AbbVie | argenx | |
|---|---|---|
| $506 billion | $58.2 billion | |
| 6.9% | 31.1% | |
| +6.0% | +116.2% | |
| 119.7× | 45.1× | |
| 3.5 years | Net cash | |
| 12.0% | 11.7% | |
| 3.1% | – |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: AbbVie vs AstraZeneca · AbbVie vs Becton, Dickinson and · AbbVie vs Bristol-Myers Squibb · AbbVie vs Boston Scientific · argenx vs Johnson & Johnson · argenx vs Eli Lilly · argenx vs Merck & · argenx vs Roche

